Scientists wary of bird flu pandemic 'unfolding in slow motion'
Corrects Wendy Barclay's affiliation in last paragraph
By Julie Steenhuysen and Jennifer Rigby
CHICAGO/LONDON, July 1 (Reuters) -Scientists tracking the spread of bird flu are increasingly concerned that gaps in surveillance may keep them several steps behind a new pandemic, according to Reuters interviews with more than a dozen leading disease experts.
Many of them have been monitoring the new subtype of H5N1 avian flu in migratory birds since 2020. But the spread of the virus to 129 dairy herds in 12 U.S. states signals a change that could bring it closer to becoming transmissible between humans. Infections also have been found in other mammals, from alpacas to house cats.
"It almost seems like a pandemic unfolding in slow motion," said Scott Hensley, a professor of microbiology at the University of Pennsylvania. "Right now, the threat is pretty low ... but that could change in a heartbeat."
The earlier the warning of a jump to humans, the sooner global health officials can take steps to protect people by launching vaccine development, wide-scale testing and containment measures.
Federal surveillance of U.S. dairy cows is currently limited to testing herds before they cross state lines. State testing efforts are inconsistent, while testing of people exposed to sick cattle is scant, government health officials and pandemic flu experts told Reuters.
"You need to know which are the positive farms, how many of the cows are positive, how well the virus spreads, how long do these cows remain infectious, the exact transmission route," said Dutch flu virologist Ron Fouchier of the Erasmus Medical Center in Rotterdam.
Dr. Jeanne Marrazzo, director of the U.S. National Institute of Allergy and Infectious Diseases, said surveillance for humans is "very, very limited."
Marrazzo described the U.S. Centers for Disease Control and Prevention’s human flu surveillance network as "really a passive reporting, passive presentation mechanism." The U.S. Department of Agriculture is more proactive in testing cows, but does not make public which farms are affected, she said.
Several experts said differing approaches from animal and human health agencies could hamper a quicker response.
“If you were designing the system from scratch, you would have one agency," said Gigi Gronvall, a biosecurity expert at the Johns Hopkins Center for Health Security. "This is not the only example where we have environmental or animal problems that cause human problems.”
A USDA spokesperson said the agency is working "around the clock" with CDC and other partners in a “whole-of-government response," adding that ongoing research shows "America’s food supply remains safe, sick cows generally recover after a few weeks, and the risk to human health remains low.”
The CDC in a statement said it, "USDA, and state and local health departments across the country have been preparing for the emergence of a novel influenza virus for nearly 2 decades and continually monitor for even the smallest changes in the virus."
'A NOTE OF CAUTION'
Some pandemics, including COVID-19, arrive with little warning. In the last flu pandemic, caused by H1N1 in 2009, the virus and its predecessors had first spread among animals for several years, Hensley said, but more surveillance would have helped health authorities prepare.
Three people in the U.S. have tested positive for H5N1 avian flu since late March after contact with cows, experiencing mild symptoms. One person in Mexico was infected with a separate H5 strain not previously seen in humans, and with no known exposure to animals. Other cases were reported in India, China and Australia, caused by different strains.
The World Health Organization says H5N1's risk to humans is low because there is no evidence of human transmission. Some tools are available if that changes, including limited amounts of existing H5N1 vaccine and antiviral medications like Tamiflu.
There are mechanisms to launch larger-scale production of tests, treatments and vaccines, if needed, said the U.N. agency's head of flu, Wenqing Zhang.
Other experts said there is sufficient concern to start preparing for potential spread in humans, although triggers for taking action differ depending on the role played in the response, said Richard Hatchett, chief executive of the Coalition for Epidemic Preparedness Innovations (CEPI). His organization acted early on funding COVID vaccine development, and is now in talks with research partners about H5N1.
CEPI aims to create a library of prototype vaccines for pathogens with pandemic potential. This would help drugmakers initiate large-scale production and distribute shots where necessary within 100 days of an outbreak.
Some countries are taking steps to protect people against H5N1. The United States and Europe are securing doses of “pre-pandemic” flu vaccine that could be used for high-risk groups, including farm or lab workers. Finland is expected to become the first country to inoculate fur and poultry farm workers, as well as animal health response workers.
Expanding vaccine access is also complex, said the WHO's Zhang. Manufacturers of potential pandemic flu vaccines make seasonal flu shots and cannot produce both at once, she said.
Since most flu vaccines are made using virus grown in eggs, it could take up to six months to produce pandemic shots. The U.S. is in talks with Moderna MRNA.O to use their faster mRNA technology for pandemic flu shots.
The experts all acknowledged a need to balance acting quickly to avert a threat versus overreacting.
"We want to sound a note of caution," said Wendy Barclay, a virologist at Imperial College London who also advisesthe UK Health Security Agency on avian flu, "without saying the world is about to end."
Reporting by Jennifer Rigby and Julie Steenhuysen; editing by Michele Gershberg and Bill Berkrot
면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.
온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.
이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.
